| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant therapy of cutaneous melanoma: the interferon debate
|
Kefford, R.F.
|
|
|
14 |
3 |
p. 358-365
|
article
|
| 2 |
ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II study
|
Smit, E.F.
|
|
|
14 |
3 |
p. 455-460
|
article
|
| 3 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
|
Ychou, M.
|
|
|
14 |
3 |
p. 481-489
|
article
|
| 4 |
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer
|
Paridaens, R.
|
|
|
14 |
3 |
p. 433-440
|
article
|
| 5 |
Cancer physicians’ attitudes toward colorectal cancer follow-up
|
Earle, C.C.
|
|
|
14 |
3 |
p. 400-405
|
article
|
| 6 |
CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection
|
Damiani, D.
|
|
|
14 |
3 |
p. 475-480
|
article
|
| 7 |
Comment on the Symposiumarticle “Fertility after treatmentfor Hodgkin’s disease”, byZ. Blumenfeld, E. Dann, I. Aviviet al. (Ann Oncol 2002; 13 Suppl 1:138–147)
|
Bohlmann, M.K.
|
|
|
14 |
3 |
p. 499
|
article
|
| 8 |
Communication, quality of life and age: results of a 5-year prospective study in breast cancer patients
|
Kerr, J.
|
|
|
14 |
3 |
p. 421-427
|
article
|
| 9 |
Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer
|
Anelli, A.
|
|
|
14 |
3 |
p. 428-432
|
article
|
| 10 |
Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients
|
Millward, M.J.
|
|
|
14 |
3 |
p. 449-454
|
article
|
| 11 |
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
|
Aapro, M.S.
|
|
|
14 |
3 |
p. 441-448
|
article
|
| 12 |
Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
|
Gonzalez, G.
|
|
|
14 |
3 |
p. 461-466
|
article
|
| 13 |
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer:long-term follow-up results of the adjCCA-01 trial
|
Arkenau, H.T.
|
|
|
14 |
3 |
p. 395-399
|
article
|
| 14 |
I. Higginson, A. Carr, P. Robinson (eds). Quality of Life
|
Tamburini, M.
|
|
|
14 |
3 |
p. 503
|
article
|
| 15 |
Immunomodulation in colorectal cancer: disappointment or promise?
|
Pentheroudakis, G.
|
|
|
14 |
3 |
p. 349-351
|
article
|
| 16 |
Interaction between paclitaxel and warfarin
|
Thompson, M.E.
|
|
|
14 |
3 |
p. 500
|
article
|
| 17 |
In this issue
|
|
|
|
14 |
3 |
p. 504
|
article
|
| 18 |
J. Lugton. Communicating with dying people and their relatives
|
Wagener, D.J.T.
|
|
|
14 |
3 |
p. 503
|
article
|
| 19 |
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
|
Bonnefoi, H.
|
|
|
14 |
3 |
p. 406-413
|
article
|
| 20 |
More on the regulation of tobacco smoke: how we got here and where next
|
Gray, N.
|
|
|
14 |
3 |
p. 353-357
|
article
|
| 21 |
Mortality from major cancer sites in the European Union,1955–1998
|
Levi, F.
|
|
|
14 |
3 |
p. 490-495
|
article
|
| 22 |
Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer
|
Kim, D.Y.
|
|
|
14 |
3 |
p. 383-387
|
article
|
| 23 |
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer
|
Licitra, L.
|
|
|
14 |
3 |
p. 367-372
|
article
|
| 24 |
Reply to Letter to the Editor on “Fertility after treatment for Hodgkin’s disease”, byM. K. Bohlmann, M. von Wolff & T. Strowitzki (Ann Oncol 2003;14: 499)
|
Blumenfeld, Z.
|
|
|
14 |
3 |
p. 499
|
article
|
| 25 |
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
|
Pivot, X.
|
|
|
14 |
3 |
p. 373-377
|
article
|
| 26 |
Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma
|
Trojan, A.
|
|
|
14 |
3 |
p. 501-502
|
article
|
| 27 |
Skin testing and hypersensitivity reactions to oxaliplatin
|
Garufi, C.
|
|
|
14 |
3 |
p. 497-498
|
article
|
| 28 |
Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome
|
Terol, M.J.
|
|
|
14 |
3 |
p. 467-474
|
article
|
| 29 |
Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-α2b
|
Gennatas, C.
|
|
|
14 |
3 |
p. 378-382
|
article
|
| 30 |
Table of Contents
|
|
|
|
14 |
3 |
p. v-vi
|
article
|
| 31 |
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
|
Mustacchi, G.
|
|
|
14 |
3 |
p. 414-420
|
article
|
| 32 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
|
Stathopoulos, G.P.
|
|
|
14 |
3 |
p. 388-394
|
article
|
Journal description